Cardura XL (doxazosin mesylate) NDC 58151-079

NDC codes

FDA NDC Directory

Product NDC (as listed)58151-079Labeler and product segments. Claims need a package NDC.

Product NDC at billing width58151-0079Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
58151-079-93	58151007993	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (58151-079-93)Marketed from Jan 4, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cardura XLSuffix: XL
Generic name (nonproprietary): doxazosin mesylate
Active ingredients: Doxazosin mesylate — 8 mg/1
Dosage form: Tablet, Film coated, Extended release
Route: Oral
Labeler: Viatris Specialty LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 021269
Marketing start: Jan 4, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha-Antagonists (Mechanism)
Identifiers: Product ID 58151-079_7fe31b0a-4fb2-427f-83e2-d5b957d6738bSPL ID 7fe31b0a-4fb2-427f-83e2-d5b957d6738bSPL set ID 355bcdce-0481-48ba-8ebd-2009106aaf77RxCUI 636360, 636361, 1242404, 1242408UNII 86P6PQK0MUUPC 0358151078936
Pharmacologic class: alpha-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N458151007993 followed by a unit qualifier and the quantity

Package 58151-0079-93. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 15, 2023.

Indications (excerpt from the label)

CARDURA ® XL is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). CARDURA XL is not indicated for the treatment of hypertension. CARDURA XL is an alpha 1 adrenergic antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. ( 1 ) CARDURA XL is not indicated for the treatment of hypertension. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 021269

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 021269
Product	Strength	Form · route	Labeler	Product NDC
Cardura XLdoxazosin mesylate	Doxazosin mesylate 4 mg/1	Tablet, Film coated, Extended releaseOral	Viatris Specialty LLC	58151-078